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Abstract
Background: Treatment of spasticity poses a major challenge in amyotrophic lateral sclerosis (ALS) patient management.
Delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (THC:CBD), approved for the treatment of
spasticity in multiple sclerosis, serves as a complementary off-label treatment option in ALS-related spasticity. However,
few structured data are available on THC:CBD in the treatment of spasticity in ALS.
Method: A retrospective mono-centric cohort study was realised in 32 patients that meet the following criteria: 1)
diagnosis of ALS, 2) ALS-related spasticity; 3) treatment with THC:CBD. Spasticity was rated using the Numeric Rating Scale
(NRS). Patient’s experience with THC:CBD was assessed using the net promoter score (NPS) and treatment satisfaction
questionnaire for medication (TSMQ-9) as captured through telephone survey or online assessment.
Results: The mean dose THC:CBD were 5.5 daily actuations (range < 1 to 20). Three subgroups of patients were identified:
1) high-dose daily use (≥ 7 daily actuations, 34%, n = 11), 2) low-dose daily use (< 7 daily actuations, 50%, n = 16), 3)
infrequent use (< 1 daily actuation, 16%, n = 5). Overall NPS was + 4.9 (values above 0 express a positive recommendation
to fellow patients). Remarkably, patients with moderate to severe spasticity (NRS≥ 4) reported a high recommendation
rate (NPS: + 29) in contrast to patients with mild spasticity (NRS < 4; NPS: − 44). For the three main domains of TSQM-9
high mean satisfaction levels were found (maximum value 100): effectiveness 70.5 (±22.3), convenience 76.6 (±23.3) and
global satisfaction 75.0 (±24.7).
Conclusion: THC:CBD is used in a wide dose range suggesting that the drug was applied on the basis of individual
patients’ needs and preferences. Contributing to this notion, moderate to severe spasticity was associated with an
elevated number of daily THC:CBD actuations and stronger recommendation rate (NPS) as compared to patients with
mild spasticity. Overall, treatment satisfaction (TSQM-9) was high. The results suggest that THC:CBD may serve as a
valuable addition in the spectrum of symptomatic therapy in ALS. However, prospective studies and head-to-head
comparisons to other spasticity medications are of interest to further explore the effectiveness of THC:CBD in the
management of spasticity, and other ALS-related symptoms.
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Background
Amyotrophic lateral sclerosis (ALS) is a severe, progres-
sive and incurable neurodegenerative disorder of the
upper and lower motor neurons [1, 2]. Patients with pre-
dominant upper motor neuron degeneration present with
spasticity that is found in 40% of all ALS patients [3].
Spasticity is defined as a velocity-dependent increase in
muscle tone in response to an externally imposed stretch
or during voluntary movement. Spasticity of the extrem-
ities, trunk and bulbar region is associated with central
paresis of upper and lower limbs, impaired trunk function,
and a pseudobulbar syndrome leading to dysarthria and
dysphagia. Beyond the functional effects in mobility, the
increase in the muscle tone of spastic muscle groups is
perceived as debilitating. It can cause muscle fibrosis, joint
contractures, muscle cramps, and pain [4].
The treatment of spasticity is a main challenge in ALS
treatment. Baclofen, tizanidine, and benzodiazepines are
used to reduce spasticity in patients with ALS. However,
these drugs demonstrate considerable limitations in effi-
cacy and tolerability. One of the particular difficulties in
ALS is in the combination of spasticity with lower motor
neuron symptoms, which can be aggravated by spasticity
regimes. Due to these challenges and limitations, there is
a great demand for other pharmacological treatment op-
tions for spasticity associated with ALS [5–8]. In the past
decade, several clinical studies have shown the safety
and efficacy of tetrahydrocannabinol (THC) and canna-
bidiol (CBD) in the control of spasticity in people with
multiple sclerosis (MS). THC:CBD (brand name Sativex)
was approved for the treatment of spastic symptoms in
patients with MS in 2011. This drug is a mixture of bo-
tanical extracts from the flowers and leaves of the hemp
plant Cannabis sativa L., folium cum flore, which con-
tains standardised concentrations of THC and CBD [9–
11]. Given the efficacy and availability of THC:CBD in
MS, this drug is increasingly being used off-label for
spasticity treatment of persons with ALS.
In ALS, THC:CBD is used mostly as escalation therapy
if symptoms cannot be adequately controlled or palli-
ation achieved with baclofen or tizanidine. Only recently,
a first phase 2 study provided preliminary evidence of ef-
ficacy and safety of THC:CBD compared with placebo in
controlling spasticity in ALS [12]. This trial showed sig-
nificant improvements in scores on the Modified Ash-
worth Scale, and some evidence of an additional
beneficial effect on spasticity-related pain. Despite the
off-label use of THC:CBD in ALS since 2011, and the
emerging evidence for efficacy in ALS-associated spasti-
city so far few structured data are available on patient
reported outcomes of ALS patients who received spasti-
city treatment with THC:CBD. The aim of this registry
study was to explore the real world experience in the
use of a standardised oromucosal spray containing THC:




The observational study was conducted as a retrospect-
ive, monocentric, cross-sectional cohort study. The in-
vestigation was reported according to the STROBE
criteria [13].
Participants
Subjects who participated in the cohort study met the
following inclusion criteria: 1) diagnosis of ALS (ICD-10
G12.2) according to the revised El Escorial criteria [14];
2) presence of spasticity; 3) treatment with THC:CBD
oromucosal spray (Sativex®); 4) consent to participate in
the study; 5) participation in a case management pro-
gram for ALS medication; 6) consent in electronic data
capture using a digital research platform [15].
Setting
Data were collected among ALS patients who were
treated in a tertiary ALS centre in Berlin (Germany).
The investigation was confined to patients treated with
THC:CBD between May 2016 and September 2017. ALS
trained neurologists confirmed the diagnosis of ALS
according to the El Escorial criteria and made the indica-
tion for the treatment with THC:CBD. The anatomic
region and severity of spasticity were classified by the
neurologist (observer reported outcome). The physician’s
classification of spasticity was assessed by the same in-
vestigator. The patient’s perception of spasticity (patient
reported outcome) was obtained during the course of
treatment. Before the patient’s assessment an instruction
to the method of numeric rating scale (NRS) was per-
formed by the investigator. Medication data on THC:
CBD and other antispasmodic drugs were recorded on
the basis of prescription data tracked on the APST
platform. Data entry of prescription data was performed
by data managers trained in the digital capture of medi-
cation data. THC:CBD was delivered via a highly stan-
dardised pump action oromucosal spray. Each 100 μL
actuation contained 2.7 mg THC and 2.5 mg CBD in a
50:50 solution of ethanol and propylene glycol.
Data capture
All observed data including demographic data, clinical
characteristics, medication data as well as scales and
scores were captured on a digital portal named "APST
platform (www.ambulanzpartner.de) [15]. Since all pa-
tients were registered on the digital platform, online self-
assessment of scales and scores was encouraged. However,
due to neurological and psychosocial limitations, online
assessment was not possible for all participants. In these
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cases, the self-assessment data were primarily collected in
a telephone interview by the investigator and subsequently
captured on the platform.
Variables
Demographic data and clinical characteristics
The following demographic data and clinical characteris-
tics were collected for all participants: age, sex, diagno-
sis, type of onset (bulbar vs spinal onset), time since
onset of symptoms, ALS severity as measured by the
ALS functional rating scale revised (ALS-FRSr), cogni-
tive impairment, region and severity of spasticity, and
antispasmodic medication. An overview of demographic
data and clinical characteristics is provided in Table 1
and the Additional file 1.
Numeric rating scale (NRS)
The patient’s perception of spasticity and of spasticity-
associated pain and cramps was recorded on the NRS, a
one-dimensional assessment tool for recording the in-
tensity of a symptom [16–19]. The 11-point scale ranges
from 0 (no complaints) to 10 (worst imaginable com-
plaints). The complaints are classified into four groups:
None: 0 points.
Mild: 1 to 3 points.
Moderate: 4 to 6 points.
Severe: 7 to 10 points.
Treatment with THC:CBD and other antispasmodic
medication
Dose of THC:CBD For THC:CBD, the number of actu-
ations per day, each containing 2.7 mg THC and 2.5 mg
CBD, was documented.
Discontinuation of THC:CBD The date of discontinu-
ation of THC:CBD treatment was recorded. The clinical
characteristics of individual patients who terminated
THC:CBD is provided in the Additional file 1. Adverse
effects of THC:CBD and causes for the discontinuation
of drug treatment were not collected within the scope of
this study.
Antispasmodic medication other than THC:CBD
Data on the prescription (generic name, prescribed dose)
of antispasmodic drugs other than THC:CBD were re-
corded. The treatment with baclofen, tizanidin, danta-
macrin and botulinum toxin (in combination with THC:
CBD) is provided in the Additional file 1.
Net promoter score (NPS)
The NPS was used for examining the patients’ attitude to-
wards their treatment with THC:CBD. This metric is cal-
culated based on responses to a single question: “How
likely is it that you would recommend THC:CBD to a
friend or colleague who suffers from ALS and spasticity?”
The answers were rated on a numeric scale between 0
(absolutely unlikely recommendation) and 10 (highest
likelihood of recommendation) points. The scores were
assessed based on the following classification [20, 21]:
10 or 9 points: Likely recommendation:
8 or 7 points: Indifferent recommendation:
6 to 0 points: Unlikely recommendation:
Patients who respond with a score of 9 to 10 are con-
sidered as “promoters”. Those who rate the medication
with 7 or 8 are classified as “indifferent”. The group of
patients who express an unlikely recommendation (6 to
0 points) are defined as “detractors”. The NPS is calcu-
lated by subtracting the percentage of patients who are
detractors from the percentage of patients who are pro-
moters. Indifferent patients count toward the total num-
ber of respondents, thus decreasing the percentage of
detractors and promoters. The NPS is the difference be-
tween persons with likely and unlikely recommendation,
which is calculated as follows:
NPS = “promoters” (in % of all patients surveyed)
minus “detractors” (in % of all patients surveyed).
The range of values of the NPS is between positive (+)
100 and negative (−) 100. An NPS with a positive score
(greater than zero) is regarded as a supporting recommen-
dation. An NPS of + 50 is considered as excellent [19, 20].
Treatment satisfaction questionnaire for medication
(TSQM-9)
Satisfaction with THC:CBD treatment was assessed by
means of TSQM-9. This score is a validated assessment
Table 1 Demographical and clinical characteristics of the study participants
Characteristics Classification Value
Gender female, male, n (%) 25 (56.8), 19 (43.2)
Age in years mean (SD) 57.3 (± 15.3)
Type of onset spinal, bulbar, n (%) 42 (95.5), 2 (4.5)
Disease duration (months) mean (SD) 58.4 (± 45)
ALS Functional Rating Scale revised mean (SD) 23.0 (± 9.2)
Presence of cognitive impairment n (%) 3 (6.8)
n Number of patients; SD standard deviation
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scale containing nine questions concerning patients’
satisfaction with medication [22, 23]. TSQM-9 was also
validated for the German language [24]. The questions
are answered on a five-point or seven-point scale (for ex-
ample, from very dissatisfied to very satisfied). Each of the
nine questions is evaluated in a total score that can range
from 0 to 100. A higher total score equates to greater
satisfaction. The total score is calculated as follows:
Total score for question X = ((response score of question
X minus 1) ÷ (highest possible response score minus the
lowest possible response score) multiplied by 100).
The questions of TSQM-9 refer to three dimensions:
effectiveness (questions 1 to 3), convenience (questions
4 to 6) and global satisfaction (questions 7 to 9). In
addition to the calculation of the total score for the nine
individual questions of TSQM-9, a score can also be
calculated for the three dimensions of effectiveness, con-
venience and global satisfaction. In this calculation also,
the total score of the three dimensions can be between 0
and 100. A higher total score equates to greater satisfac-
tion. The total scores for effectiveness, convenience and
global satisfaction are calculated as follows:
Total score for effectiveness: ([sum (response score for
question 1 plus question 2 plus question 3) minus 3]
divided by 18) multiplied by 100.
Total score for convenience: ([sum (response score for
question 4 plus question 5 plus question 6) minus 3]
divided by 18) multiplied by 100.
Total score for global satisfaction: ([sum (response score
for question 7 plus question 8 plus question 9) minus 3]
divided by 14) multiplied by 100.
Protocol approvals and registrations
The study protocol was approved by the Medical Ethics
Committee of the Charité – Universitätsmedizin Berlin,
Germany under the number EA1/219/15. A signed
patient information and informed consent form was
obtained from all participating patients.
Data analysis
Descriptive statistics were used for the statistical analysis
(frequency in percent, mean, median, standard deviation
in ±). Differences of frequencies between subgroups
were assessed by Fisher’s exact test or Chi-square test. P
values have been reported with a 95% confidence inter-
val. The data were analysed using SPSS (version 24.0).
Results
Sample characteristics
A total of 68 patients with ALS were invited to partici-
pate in the questionnaire. 44 patients participated in the
study (65%). Data sets were collected through online as-
sessment (n = 18) or in a telephone survey (n = 26). One
patient, being completely paralysed (ALS-FRSr = 0 of 48
score points), used an eye-controlled communication de-
vice for completion of the questionnaire. In the cohort
of 44 patients, a complete dataset was obtained for 32
subjects (Fig. 1).
Demographic data and clinical characteristics
Of the patients surveyed, 56.8% (n = 25) were women
and 43.2% (n = 19) were men. At the time of the survey,
the average age of the respondents was 57.3 years (±
15.3; median: 57.5). The majority of participants (56.8%;
n = 25) were between 41 and 70 years old. Twenty-five
percent (n = 11) were older than 70 years. At the time of
the survey, the youngest patient was 27 years old and the
oldest patient was 87 years. Mean disease duration since
symptom onset was 58.4 months (± 45 months; median:
42 months). 95.5% of the patients showed a spinal symp-
tom onset. The ALS-FRS score was 23 scale points (±
9.2 scale points) as compared to the maximum number
of 48 scale points. In 6.8% of the patients (n = 3) clinical
signs of frontotemporal lobe degeneration were de-
scribed. A summary of demographic and clinical data is
summarised in Table 1. The clinical characteristics of
individual patients is provided in the Additional file 1.
Location and severity of spasticity
The majority of the patients in the study (95.5%; n = 42)
showed spasticity of the lower extremities, either limited
to the legs or in combination to spasticity of the upper
extremities. 29.5% of the patients (n = 13) had only spas-
ticity in the lower extremities, all of whom had a spinal
onset. Spasticity of the arms, either limited to the arms
or in combination to spasticity of the lower limbs, was
found in 68.2% (n = 30) of patients. Only one of the
study patients showed spasticity confined to the upper
extremities (2.3%). In a classification of severity of spasti-
city into severe, moderate and mild, there were regional
differences in the severity level of spasticity. In the lower
extremities, severe spasticity was frequently described
(33.3% of patients). A contrasting constellation was
found in the arms: Severe spasticity was rarely demon-
strated (7.1%). In the arms mild spasticity prevailed
(72.5%), in contrast to the lower limbs were mild severity
was rarely found (17.5%; Fig. 2).
Perception of spasticity
Most of the patients considered spasticity as a severe
(24.2%, n = 8) or moderate (48.5%, n = 16). A small num-
ber of patients (6.1%; n = 2) had no perception of spasti-
city. In those patients, spasticity was demonstrated in
the neurologist’s investigation, whereas the patient had
no subjective perception for the symptom.
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Perception of pain and cramps
Spasticity-associated pain and cramps were a common
symptom in the examined cohort. Of the surveyed ALS
patients, 70% (n = 23) reported pain. In 51.5% (n = 17), the
pain was moderate to severe. 84.4% of patients (n = 27)
reported cramps. In 59.4% (n = 19), the cramps were mod-
erate to severe.
Treatment with THC:CBD and other antispasmodic
medication
Dose range of THC:CBD
The mean dose THC-CBD were 5.5 daily actuations (±
5.1; range < 1 to 20). The daily dose of THC:CBD, as
assessed by the number of actuations per day, showed a
wide range among the studied patients (Fig. 3). Three
distinct subgroups of patients were identified: 1) high-
dose daily use (7 or more daily actuations, 34% of
patients, n = 11), 2) low-dose daily use (six or less daily
actuations, 50% of patients, n = 16), 3) low-dose less then
daily use (less than one daily actuation, 16% of patients,
n = 5). 6.2% of the studied patients (n = 2) used more
than 12 and up to 20 actuations per day.
Discontinuation of THC:CBD
40% of the studied patients (n = 16) discontinued THC:
CBD treatment during the observation period.
Dose of THC:CBD in relation to severity of spasticity
For the treatment of lower limb spasticity, a correlation
of symptom severity and the applied THC:CBD dose
was found (Fig. 4). In patients with severe spasticity, a
mean number of 7.3 actuations (± 6.0) were used,
whereas in patients with mild spasticity 3.3 daily actua-
tions (± 5.8) were reported.
Antispasmodic medication other than THC:CBD
25% of patients (n = 10) received other antispasmodic
medication in combination with THC:CBD. Baclofen
was used in 25% of patients (n = 10) whereas tizanidine
was observed in 5% of studied individuals (n = 2). None
of the patients received dantamacrin or botulinum toxin
in combination with THC:CBD.
Net promoter score (NPS)
The patient’s attitude towards their treatment with
THC:CBD, as assessed by NPS, is shown in Fig. 5. The
overall NPS score was + 4.9 points. This evaluation is
considered a positive attitude of patients towards THC:
CBD as a NPS higher than zero is generally deemed
good [20]. Remarkably, patients with moderate to severe
spasticity (NRS ≥ 4) had a very high likelihood (NPS: +
28) to recommend THC:CBD, just in contrast to pa-
tients with mild spasticity (NRS < 4; NPS: − 44).
Treatment satisfaction questionnaire for medication
(TSQM-9)
Detailed results for individual TSQM-9 questions
The patients’ treatment satisfaction with THC:CBD, as
assessed by TSQM-9, is shown in Fig. 6. The score was
evaluated separately in the nine addressed questions,
which are as follows.
TSQM-9, Question 1 (effectiveness) – ability of THC:
CBD to prevent or treat spasticity: 94% of patients (n = 30)
were reasonably to very satisfied with the ability of THC:
CBD for the treatment of spasticity.
TSQM-9, Question 2 (effectiveness) – the way
THC:CBD relieves spasticity: 91% of patients (n = 29)
Fig. 1 Sample characteristics. A total number of ALS patients at the
study site fullfilling the inclusion criteria were invited to participate in
the survey. A subgroup responded and participated in the study. Data
were collected online or via telephone survey. Data sets for severity of
spasticity (Numeric Rating Scale, NRS), recommendation of treatment
(Net Promoter Score, NPS) and treatment satisfaction (Treatment
Satisfaction Questionnaire for Medication, TSQM-9) were obtained. n =
number of patients and analysable datasets, respectively
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were reasonably satisfied to very satisfied with the
way how THC:CBD alleviated the symptoms of
spasticity.
TSQM-9, Question 3 (effectiveness) – amount of time
it takes THC:CBD to start working: 91% of patients
(n = 29) were reasonably satisfied to very satisfied with
the time it takes THC:CBD to alleviate spasticity.
TSQM-9, Question 4 (convenience) –usability of
THC:CBD: 69% of patients (n = 22) considered the use
of THC:CBD in its current form as being relatively easy
to very easy. To be noted, however, there was a substan-
tial percentage in the cohort (31%; n = 10) regarding the
use of THC:CBD as difficult.
TSQM-9, Question 5 (convenience) –planning when
to use THC:CBD: 94% of patients (n = 30) considered
the plan when to use THC:CBD each time as being rela-
tively easy to very easy.
TSQM-9, Question 6 (convenience) – administration
of THC:CBD as instructed: 84% of patients (n = 27) con-
sidered the administration of THC:CBD as instructed as
being relatively easy to very easy. However, there was a
substantial percentage in the cohort (16%; n = 5) regard-
ing the administration of THC:CBD as inconvenient or
very inconvenient.
TSQM-9, Question 7 (global satisfaction) – taking
THC:CBD is a good thing: 84% of patients (n = 27) were
Fig. 2 Location and severity of spasticity. The location of spasticity in terms of upper and lower limb involvement is shown. The severity of
spasticity, as assessed by neurologists, was classified into severe, moderate and mild spasticity. It was recorded on a 4-point scale and classified as
follows: severe spasticity: 4 points, moderate spasticity: 3 points, mild spasticity: 2 points, no spasticity: 1 point
Fig. 3 Dose distribution in the use of THC:CBD. Maximum number of actuations per day. The daily dose of THC:CBD, as assessed by the
maximum number of actuations per day, is shown. Number of patients = 32
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relatively convinced to very convinced that taking THC:
CBD was a good thing for the patient. Remarkably, 16%
of patients (n = 5) took THC:CBD even though they
were not completely convinced or not all convinced of
the medication.
TSQM-9, Question 8 (global satisfaction) – the good
things about THC:CBD outweigh the bad things: 78% of
patients (n = 25) were relatively certain to very certain
that the good things about THC:CBD outweigh the bad
things. To be noted, however, there was a substantial
percentage in the cohort (22%; n = 7) take used THC:
CBD even though they were not completely certain or
not at all certain that the positive aspects outweigh the
negative side of the medication.
TSQM-9, Question 9 (global satisfaction) – overall sat-
isfaction THC:CBD: 91% of patients (n = 29) were, taking
all things into account, reasonably satisfied to very
satisfied with the medication of THC:CBD.
Total score for individual TSQM-9 questions
The total score for all TSQM-9 items (questions 1 to 9)
is shown in Table 2. The highest satisfaction was found
for the planning when to use THC:CBD (question 5;
total score 87.5; ± 20.3) and overall satisfaction (question
9; total score: 79.2; ± 22.8). Reduced satisfaction was
identified in the usability of THC:CBD (question 4; total
score: 65.6; ± 38.6) and in the latency of THC:CBD to
start working (question 3; total score: 66.2; ± 24.1).
Total score for main TSQM-9 domains
For the three main domains of TSQM-9 high satisfaction
levels were found, which are as follows: effectiveness –
mean score 70.5, ± 22.3; convenience – mean score 76.6,
± 23.3; global satisfaction – mean score: 75.0, ± 24.7.
Discussion
Sample selection
The present report examines the treatment of ALS-
related spasticity using THC:CBD. Systematic assess-
ment of “real world experience” was facilitated by the
use of a digital management platform [25]. Currently,
more than 1.600 ALS patients are registered on that
platform representing a substantial fraction of the ALS
population in Germany [14]. The digitization of drug
management allowed the tracking and systematic ana-
lysis of real world use of THC:CBD in ALS. Despite the
advantages of the platform-based registry and substantial
number of analysed patients with off-label use of THC:
CBD several limitations have to be addressed. The study
cohort was monocentric and covered a rather small sam-
ple size. Given the limited sample size the statistical ana-
lysis was therefore confined to descriptive methods.
Furthermore, a subgroup of patients did not respond to
the study invitation (n = 24; 35%). The reasons for non-
responding was not explored systematically. Therefore,
an observation bias in the cohort of participating
patients – as compared to the group of patients who d-
eclined study participation – has to be considered. Fur-
thermore, the platform-approach and the study site
being a tertiary ALS centre may have created some fur-
ther observation bias. Therefore, it is conceivable that
more intensive THC:CBD treatment may be overrepre-
sented in this cohort while drug treatment of less com-
plex ALS phenotypes was provided independently from
the platform, i. e. outside the analysed data set. More-
over, 7% of studied patients (n = 3) showed mild signs of
frontotemporal lobe degeneration by means of a dysexe-
cutive syndrome. Given the rather low grade of neuro-
psychological syndrome we opted to include the data of
Fig. 4 Dose of THC:CBD in relation to severity of spasticity. THC:CBD dose was defined as maximum number of THC:CBD actuations per day (mean,
maximum and minimum number). Severity of spasticity was assessed by neurologists using a 4-point scale: no spasticity (1 point); mild spasticity (2
points); moderate spasticity (3 points); severe spasticity (4 points). Data are shown for spasticity of the lower extremities. Number of patients = 32
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those patients. Therefore, some distortion of patient re-
ported data cannot be excluded in this particular group
of patients.
Severity and perception of spasticity
Severity of spasticity was classified by the ALS-trained
neurologists in three main categories (severe, moderate,
mild). The physician’s assessment of spasticity was
narrowed to these main graduations as functional as-
pects of treatment was not the emphasis of this study.
However, in further investigations a more precise classi-
fication and functional assessments of spasticity (before
and after initiation of THC:CBD treatment) are of main
interest. The Ashworth Scale, which has been used in
some previous ALS studies, was not applied given its
limitations [6]. The score does not reflect the possible
co-existence of spasticity with lower motor neuron in-
volvement which is specific for ALS. Furthermore, this
score might not represent the patients’ subjective per-
ception of spasticity. In an attempt to overcome these
limitations, a diseasespecific selfreported scale, the ALS
spasticity index (SI-ALS) has been developed. However,
the SI-ALS was released only recently, well after our
study had been completed [26]. In our study, both the
neurologist’s classification of spasticity, and the patient’s
subjective perception of spasticity were obtained. By that
means, we found that most of the patients treated with
THC:CBD perceived severe or moderate spasticity (60 to
77%, Fig. 3). In a smaller group of patients (14 to 23%,
Fig. 3), low-grade spasticity was reported. It is uncertain
Fig. 5 Patients’ recommendation of THC:CBD overall and in relation to severity of spasticity. The likelihood of recommendation of THC:CBD in the
overall patient group and in relation to the severity of spasticity (a) was assessed using the Net Promoter Score (NPS): unlikely recommendation (0 to 6
points); indifferent recommendation (7 to 8 points); likely recommendation (9 to 10 points). The patients’ perception of spasticity was assessed using
the Numeric Rating Scale (NRS): Patients with moderate to severe spasticity (NRS≥ 4), patients with mild or no spasticity (NRS < 4). The total NPS (b) is
calculated by subtracting the percentage of patients who are detractors from the percentage of patients who are promoters. Patients who respond
with a score of 9 to 10 are considered as “promoters”. Those who rate the medication with 7 or 8 are classified as “indifferent” (not shown in b). The
group of patients who express an unlikely recommendation (6 to 0 points) are defined as “detractors”. n = number of patients
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Fig. 6 (See legend on next page.)
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whether those patients were treated with a-priori lower-
grade spasticity or THC:CBD may have achieved
symptom control in those patients. In principle, an
therapeutic effect of THC:CBD is conceivable as in a
recent phase 2 trial (CANALS study) THC:CBD was re-
ported to reduce spasticity in ALS [12]. However, given
the non-interventional study design, our data provided
little opportunity to interpret the reduced muscle tonus
as response to THC:CBD. Beyond spasticity, the percep-
tion of pain and muscle cramps was documented. Both
spasticity-associated symptoms were highly prevalent in
the studied cohort (70% pain; 84% muscle cramps). In
other ALS cohorts, the prevalence of pain has been re-
ported to be as high as 51–80% [27, 28]. Cannabinoids
are increasingly recognised as a treatment option in
neuropathic and nonneuropathic pain [29, 30]. However,
a study of NPS and TSQM-9 in the context of ALS-re-
lated pain was not subject of this registry study.
Dose of THC:CBD
Our study, to our knowledge, provided the first real
world data (outside a clinical trial) on the dosing of
THC:CBD in ALS. In the CANALS study, a mean dose
of daily 8.2 actuations (SD 2.9; range 1 to 12) was re-
ported [12]. In our cohort the mean dose was slightly
lower (6 daily actuations). More importantly, a wider
range in the daily dose was identified (± 4; range < 1 to
20). Basically, in the treatment with oromucosal spray of
THC:CBD, patients were instructed to self-titrate during
the first 14 treatment days following a predefined escal-
ation regime to their optimal dose, up to 12 daily actua-
tions, with the aim of balancing symptom control and
unwanted effects. Despite this general instruction, a di-
versity of individual dose regimes was reported. For rea-
sons of clarity, three distinct use pattern of THC:CBD
were defined: 1) high-dose daily use (7 or more actua-
tions, 34%), 2) low-dose daily use (6 to 1 daily actua-
tions, 50%), 3) low-dose less than daily use (< 1 daily
actuation, 16%). The distinction between high vs. low-
dose use was made at the mean number 6 actuations per
day. Patients of the high-dose group (34%) were treated
with THC:CBD doses for that clinical trials in ALS and
MS have demonstrated alleviation of spasticity [9–11].
Presumably, this patient group benefited most from
THC:CBD treatment. A correlation of symptom severity
and the applied THC:CBD dose was found (Fig. 4). In
patients with severe lower limb spasticity, a mean num-
ber of 7.3 actuations (± 6.0) were used, whereas in pa-
tients with mild spasticity 3.5 (± 2.2) daily actuations
were reported. In patients with low-dose daily use the
efficiency of THC:CBD treatment is not excluded but
yet uncertain as long there are no dose-range studies
completed. In patients with less than daily use, an epi-
sodic use on demand in terms of escalation therapy of
fluctuating spasticity is conceivable. However, the treat-
ment modalities in this group of patients have not been
studied yet. Further studies are needed to define the
dose correlation and minimum effective dose of THC:
CBD in ALS-related spasticity. Remarkably, 40% of the
patients discontinued the treatment of THC:CBD within
the observation period. So far, we have not identified
demographic or clinical characteristics (such as age,
disease duration or disease severity) that correlated with
termination of THC:CBD (data shown in additional file
1). Reasons for discontinuation of treatment were not in
the scope of this non-interventional cohort study. In
future studies, a systematic analysis of adverse events
(See figure on previous page.)
Fig. 6 The patient’s treatment satisfaction with THC:CBD, as assessed by Treatment Satisfaction Questionnaire for Medication (TSQM-9). The score
was evaluated separately in nine questions, which are as follows. Question 1 (a) – ability of THC:CBD to prevent or treat spasticity: “How satisfied
or dissatisfied are you with the ability of THC:CBD to prevent or treat your spasticity?”; Question 2 (b) – the way THC:CBD relieves spasticity: “How
satisfied or dissatisfied are you with the way THC:CBD relieves your symptoms?”; Question 3 (c) – amount of time it takes THC:CBD to start
working: “How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?”; Question 4 (d) – usability of
THC:CBD: “How easy or difficult is it to use the medication in its current form?”; Question 5 (e) – planning when to use THC:CBD: “How easy or
difficult is it to plan when you will use the medication each time?”; Question 6 (f) – administration of THC:CBD as instructed: “How convenient or
inconvenient is it to take the medication as instructed?”; Question 7 (g) – taking THC:CBD is a good thing: “Overall, how confident are you that
taking this medication is a good thing for you?”; Question 8 (h) – the good things about THC:CBD outweigh the bad things: “How satisfied are
you that the good things about this medication outweigh the bad things?”; Question 9 (i) – overall satisfaction THC:CBD: “Taking all things into
account, how satisfied or dissatisfied are you with this medication”; n = number of patients
Table 2 Total score of Treatment Satisfaction Questionnaire for
Medication (TSQM-9)
Questions Q 1 Q 2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Mean Score 73.5 71.9 66.2 65.6 87.5 76.6 72.7 71.1 79.2
STD 24.6 26.2 24.1 38.6 20.3 32.5 29. 3 33.7 22.8
The patients’ treatment satisfaction with THC:CBD, as assessed by Treatment
Satisfaction Questionnaire for Medication (TSQM-9). The score was evaluated
separately in nine questions. Each of the nine questions is evaluated in a total
score that can range from 0 to 100. A higher total score equates to greater
satisfaction. Question (Q) 1 – ability of THC:CBD to prevent or treat spasticity;
Q 2 – the way THC:CBD relieves spasticity; Q 3 – amount of time it takes
THC:CBD to start working; Q4 – usability of THC:CBD; Q 5 – planning when to
use THC:CBD; Q 6 – administration of THC:CBD as instructed; Q 7 – taking
THC:CBD is a good thing; Q 8 – the good things about THC:CBD outweigh the
bad things; Q 9 – overall satisfaction THC:CBD; n number of patients. STD
standard deviation
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and side effects is warranted in order to determine the
benefit-risk profile of THC:CBD in the treatment of
ALS-related spasticity.
Recommendation of THC:CBD by patients
The NPS serves as a robust instrument for the assess-
ment of products and services, which is used mostly out-
side of medicine [20, 21]. This likely-to-recommend
question is considered to exhibit behaviour in response
to user experience. Although the validation of this score
in medicine is still limited, the NPS finds growing use in
outcome research, mainly due to the simplicity of the
method and the established calculation matrix [31, 32].
In the overall group of patients there was a NPS score of
+ 4.9 that translates into a moderately positive recom-
mendation rate. Remarkably, between the patient groups
of low-grad spasticity (NRS < 4) and of moderate to
severe spasticity (NRS ≥ 4), there were noticeable differ-
ences in the NPS (p < .05). Patients with low-grade spas-
ticity were not like to recommend THC:CBD to fellow
patients (showing a negative NPS of − 44; Fig. 5). In con-
trast, patients with moderate to severe spasticity were
highly likely to recommend the treatment (demonstrat-
ing a very positive NPS of + 28). Given the low case
numbers, the significance in the differences of NPS
between the two patient groups have to be interpreted
with some caution. NPS data on THC:CBD or other
medications have not yet been published in ALS. In
particular, there are no comparative data for baclofen,
tizanidine or other antispasmodic medication. The
obtained NPS scores for THC:CBD are, therefore, to be
regarded as a baseline for further studies.
Treatment satisfaction
The evaluation of TSQM-9 showed a high overall level
of satisfaction for THC:CBD treatment in most studied
ALS patients (84% of patients gave positive results in
question 9 for global satisfaction). However, like with
NPS, the limitation with this score lied in the lack of
comparative TSQM-9 data for other spasticity medica-
tions such as baclofen and tizanidine. This limitation ad-
dresses a fundamental problem in clinical ALS research
where no systematic studies on patient reported out-
comes of symptomatic and palliative medications have
been published so far. Given the lack of comparative
data, the outcomes from TSQM-9 are to be regarded as
pilot data. The large proportion of patients stating high
overall satisfaction with THC:CBD (91%, n = 29) some-
how contrasts with smaller proportion of patients that is
ready to recommend the treatment to fellow patients
(37%, n = 11, positive NPS results). Apparently, TSQM-9
(satisfaction) and NPS (recommendation), seem to assess
distinct aspects of patients’ experience. Although there is
no comparative between TSQM-9 and NPS, it is well
conceivable that the patient’s likeliness to recommend a
therapy to other patients (NPS) is handled more
critically and more stringently than the patient’s own
satisfaction (TSQM-9). In a more analysis of TSQM-9,
the score showed difficulties among ALS patients (31%;
n = 10) in taking the medication in its current form
(TSQM-9, question 4). This finding may reflect barriers
in handling the oromucosal spray due to upper extrem-
ity paresis or due to difficulties in fully opening the
mouth. The critical use of the medication THC:CBD un-
derscores the necessity of instructions of patients and
their relatives in order to facilitate the administration of
the prescribed medication.
Unsolved issues
A comparative analysis of THC:CBD with other anti-
spasmodic medications, particularly baclofen and tizani-
dine, was not in the scope of this non-interventional
study. However, controlled studies are needed to achieve
a head-to-head comparison of THC:CBD to other anti-
spasmodic medicines preferably in a multicentric design.
Furthermore, a dose correlation of THC:CBD to symp-
tom control is of interest. Given the palliative treatment
aim in most ALS patients, symptom control may not
necessarily relate to improvement in motor function. Be-
yond function, the various dimensions of spasticity such
as muscle tone, pain, cramps, and mobility restrictions
may be modified by THC:CBD [27, 28, 33]. Contributing
to this notion, future studies, as our observational study,
should touched upon treatment aims beyond functional
endpoints. This view is supported by the results of a sys-
tematic analysis on physical therapy in ALS demonstrat-
ing an increasing patients’ treatment satisfaction despite
the continuous decline of motor function [34].
Conclusion
THC:CBD is increasingly recognised as a valuable option
in the management of spasticity in ALS. The analysis of
real world data, derived from a platform-based patient
registry, demonstrated a wide range in the dose of THC:
CBD for the treatment of ALS-related spasticity.
Obviously, THC:CBD was used on the basis of individual
patients’ needs and preferences. Furthermore, severe
spasticity was associated with an increased number of
daily THC:CBD actuations and a stronger recommenda-
tion rate on the NPS score as compared to patients with
mild spasticity. Overall, patients reported outcomes as
assessed by TSQM-9 revealed a high treatment satisfac-
tion with THC:CBD. The results of our study suggest
that THC:CBD may serve as an important addition to
the spectrum of treatment options of spasticity in ALS.
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However, an important selection bias, and by that means
limitation of the study, has to be considered as a 40% of
patients (n = 16) discontinued THC:CBD treatment dur-
ing the observation period. Further studies are warranted
to confirm our results and to address the many still open
issues in the therapeutic potential of THC:CBD in this
disorder.
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study participants. (PDF 54 kb)
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